The ARL14EP Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Jurkat T lymphocyte line. This product enables loss-of-function studies of the ARL14EP effector protein, critical for MHC class II antigen presentation. The polyclonal format preserves a heterogeneous editing landscape, providing a robust model for investigating gene function without clonal selection. These cells are optimized for immunological and oncology workflows requiring stable ARL14EP disruption.
The Jurkat host cell line originates from a human T-cell acute lymphoblastic leukemia (T-ALL) patient and is widely used to study T-cell receptor signaling, apoptosis, and lymphoblast biology. Jurkat cells are suspension-adapted lymphoblasts that express relevant surface receptors and signaling molecules, facilitating genetic manipulation and high-throughput screening. Their T-ALL background makes them suitable for evaluating immune-related perturbations, including those affecting MHC class II trafficking and T-cell activation.
ARL14EP serves as an effector of the small GTPase ARL14, promoting the transport of MHC class II molecules from endosomes to the plasma membrane. This process is regulated by IFN-?? through the CIITA/STAT1 pathway and involves interactions with ARL14, MYO1E, CD74, and actin. Downstream targets such as HLA-DR and F-actin mediate antigen presentation and cytoskeletal dynamics. Disruption of ARL14EP hinders MHC II surface delivery, impeding proper antigen presentation and immune synapse formation.
In Jurkat T cells, ARL14EP knockout provides a system to explore the consequences of impaired MHC II trafficking on T-cell activation and signaling. Although Jurkat cells are not professional APCs, they can present antigens and upregulate MHC II under certain conditions; loss of ARL14EP may therefore alter immune recognition and response. This model is relevant for studying colorectal cancer immunology, where ARL14EP may influence tumor?Cimmune interactions, and for dissecting mechanisms in immunodeficiencies and autoimmunity.
Applications include flow cytometry to quantify MHC II surface expression, western blotting for ARL14EP and interacting partners, RT-qPCR for knockout verification, and immunofluorescence to assess MHC II localization. Antigen presentation and T-cell activation assays further enable functional characterization. The cells are also suited for immune modulator screening and autoimmune disease modeling. For further information or technical inquiries, please contact Ascent Research.
